Physician profile
Daniel Dean
NPI 1689292203
$2,806.73
in general payments reported to CMS, 2019-2025
29 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.45 · 2022: $31.58 · 2023: $618 · 2024: $969 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.93 | 2023-2025 | |
| Novo Nordisk INC | $300.84 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $249.18 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $154.93 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $126.05 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $116.46 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $113.97 | 2025 | Fanapt |
| Exact Sciences Corporation | $101.29 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $96.82 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.19 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.56 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $90.49 | 2023-2025 | Rexulti |
| Medtronic, INC. | $68.14 | 2023-2024 | Intellis Adaptivestim, Venaseal |
| Pfizer INC. | $62.07 | 2024 | |
| Dexcom, INC. | $51.03 | 2024 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.89 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $41.58 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $33.61 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.82 | 2025 | Xifaxan |
| Abbott Laboratories | $22.02 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $21.47 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $18.85 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.23 | 2023 | Nuzyra |
| Abiomed | $17.41 | 2025 | |
| Currax Pharmaceuticals LLC | $14.93 | 2023 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2025 | |
| Tempus Ai, INC | $13.75 | 2024 | |
| Baxter Healthcare | $13.58 | 2022 | |
| Genentech USA, INC. | $3.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.